Wedbush Reiterates Outperform Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reissued by stock analysts at Wedbush in a research note issued to investors on Tuesday, RTT News reports. They currently have a $10.00 price objective on the stock. Wedbush’s price target suggests a potential upside of 75.75% from the company’s previous close.

Several other research analysts have also recently commented on TCRX. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a report on Monday, August 12th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $12.00.

TScan Therapeutics Stock Performance

NASDAQ TCRX opened at $5.69 on Tuesday. The stock has a fifty day simple moving average of $5.34 and a 200-day simple moving average of $6.58. TScan Therapeutics has a twelve month low of $3.73 and a twelve month high of $9.69. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08. The stock has a market cap of $301.40 million, a PE ratio of -4.90 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02. The business had revenue of $0.54 million during the quarter, compared to analyst estimates of $1.55 million. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. Equities analysts anticipate that TScan Therapeutics will post -1.17 earnings per share for the current year.

Insiders Place Their Bets

In other TScan Therapeutics news, Director Barbara Klencke purchased 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were purchased at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the purchase, the director now directly owns 40,000 shares in the company, valued at $221,200. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the transaction, the insider now owns 4,716 shares in the company, valued at approximately $27,258.48. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Barbara Klencke bought 5,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were purchased at an average price of $5.53 per share, with a total value of $27,650.00. Following the acquisition, the director now directly owns 40,000 shares in the company, valued at approximately $221,200. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 15,000 shares of company stock valued at $82,550. Insiders own 2.76% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds have recently bought and sold shares of the business. Tocqueville Asset Management L.P. acquired a new stake in shares of TScan Therapeutics in the first quarter valued at approximately $1,685,000. Vanguard Group Inc. raised its holdings in TScan Therapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after buying an additional 20,000 shares during the period. Bank of New York Mellon Corp purchased a new position in TScan Therapeutics during the 2nd quarter worth approximately $682,000. Rhumbline Advisers acquired a new position in TScan Therapeutics during the second quarter valued at $274,000. Finally, American Century Companies Inc. increased its holdings in shares of TScan Therapeutics by 48.9% in the 2nd quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock valued at $278,000 after purchasing an additional 15,596 shares during the period. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.